Atypical haemolytic uraemic syndrome associated with a CD46 mutation triggered by Shigella flexneri

Clinical Kidney Journal

Volumn 7, Issue 3, 2014, Pages 286-288

  Brocklebank, Vicky ^a   Wong, Edwin K S ^b   Fielding, Rick ^a   Goodship, Timothy H J ^a,b   Kavanagh, David ^a,b  

^a FREEMAN HOSPITAL   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

CD46; complement; haemolytic uraemic syndrome; shiga toxin; Shigella

Indexed keywords

CREATININE; HEMOGLOBIN; LACTATE DEHYDROGENASE; MEMBRANE COFACTOR PROTEIN; STEROID; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; ARTICLE; BACTERIUM ISOLATION; CASE REPORT; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE ASSOCIATION; DRUG MEGADOSE; ENZYME ACTIVITY; FEMALE; GENE MUTATION; HEMOGLOBIN BLOOD LEVEL; HEMOLYTIC UREMIC SYNDROME; HOSPITAL DISCHARGE; HUMAN; KIDNEY FUNCTION; LACTATE DEHYDROGENASE BLOOD LEVEL; NETHERLANDS; PLASMAPHERESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN URINE LEVEL; SHIGELLA FLEXNERI; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; VOMITING;

EID: 84901930791     PISSN: 20488505     EISSN: 20488513     Source Type: Journal    
DOI: 10.1093/ckj/sfu032     Document Type: Article

References (17)

1. Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producingEscherichia coli and haemolytic uraemic syndrome. Lancet 2005; 365: 1073-1086
2. Wu CJ, Hsueh PR, Ko WC. A new health threat in Europe: Shigatoxin-producing Escherichia coli O104:H4 infections. J MicrobiolImmunol Infect 2011; 44: 390-393
3. Kavanagh D, Goodship TH, Richards A. Atypical hemolyticuremic syndrome. Semin Nephrol 2013; 33: 508-530
4. Legendre CM, Licht C, Muus P et al. Terminal complementinhibitor eculizumab in atypical hemolytic-uremic syndrome.N Engl J Med 2013; 368: 2169-2181
5. Lapeyraque AL, Malina M, Fremeaux-Bacchi V et al. Eculizumabin severe Shiga-toxin-associated HUS. N Engl J Med 2011 364: 2561-2563
6. Fremeaux-Bacchi V, Moulton EA, Kavanagh D et al. Geneticand functional analyses of membrane cofactor protein(CD46) mutations in atypical hemolytic uremic syndrome.J AmSoc Nephrol 2006; 17: 2017-2025
7. Richards A, Kathryn Liszewski M, Kavanagh D et al. Implicationsof the initial mutations in membrane cofactor protein(MCP; CD46) leading to atypical hemolytic uremic syndrome.Mol Immunol 2007; 44: 111-122
8. O'Loughlin EV, Robins-Browne RM. Effect of Shiga toxin andShiga-like toxins on eukaryotic cells. Microbes Infect 2001; 3: 493-507
9. Khan WA, Griffiths JK, Bennish ML. Gastrointestinal and extraintestinalmanifestations of childhood shigellosis in a regionwhere all four species of Shigella are endemic. PLoS One 2013; 8: e64097
10. Strauch E, Lurz R, Beutin L. Characterization of a Shiga toxinencodingtemperate bacteriophage of Shigella sonnei. InfectImmun 2001; 69: 7588-7595
11. Prado D, Cleary TG, Pickering LK et al. The relation betweenproduction of cytotoxin and clinical features in shigellosis.J Infect Dis 1986; 154: 149-155
12. Loirat C, Fremeaux-Bacchi V. Atypical hemolytic uremic syndrome.Orphanet J Rare Dis 2011; 6: 60
13. Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA et al.Differential impact of complement mutations on clinicalcharacteristics in atypical hemolytic uremic syndrome. J AmSoc Nephrol 2007; 18: 2392-2400
14. Alberti M, Valoti E, Piras R et al. Two patients with history ofSTEC-HUS, posttransplant recurrence and complement genemutations. Am J Transplant 2013; 13: 2201-2206
15. Noris M, Caprioli J, Bresin E et al. Relative role of geneticcomplement abnormalities in sporadic and familial aHUSand their impact on clinical phenotype. Clin J Am Soc Nephrol 2010; 5: 1844-1859
16. Wong EK, Goodship TH, Kavanagh D. Complement therapy inatypical haemolytic uraemic syndrome (aHUS). Mol Immunol 2013; 56: 199-212
17. Kavanagh D, Richards A, Goodship T et al. Transplantation inatypical hemolytic uremic syndrome. Semin Thromb Hemost 2010; 36: 653-659